Our lab is focusing on the molecular mechanisms by which dietary nutrients can prevent cancer. We have the unique approach of combining molecular biology and epidemiology to truely assess translationally the genetic and epigenetic mechanisms regulating cancer cell and tumor growth. Starting from the Epidemiological evidence that specific dietary nutrients have a positive or negative impact on cancer risk and outcome our lab has narrowed down in vitro and in vivo on the molecular mechanisms involved in those effects. By doing so we can utilize state of the art molecular biology tools to characterize the pathways and some of the targets by which specific nutrients control cancer cell and tumor growth. Some of those include regulation of cell cycle, oxidative stress and apoptosis. The information gathered from our in vitro and in vivo models can then be used back in the human population to further validate strategies and mechanisms by which these specific nutrients maybe be effective chemopreventive agents and how their effect may differ from individual to individual. The unique approach of our lab is that the information gathered from basic research is fed back to analysis in human population and the resulting outcome tested back again in vitro in a continuous looping manner that allows true interaction between clinical and basic research. Thus using this back and forth cross-talk between basic and clinical research we are able to refine our understanding of the molecular mechanims regulating disease progression and risk in the human population. The resulting potential impact is obviously enormous for the millions of American who could benefit from cancer prevention strategies that would only require dietary manipulation.Our main sites of interest include skin, prostate, breast, liver and ovarian cancer. Some of the nutrients that have shown to be outstdanding chemopreventive agents include fatty acids, sulforophane, green tea polyphenols, phytochemicals and some vitamines. In addition, because of our location in the Cancer Institute we benefit from the close interactions and collaborations with other members of the Cancer Research Center. Finally we have taken advantage of lentiviral systems to design inducible vectors in vitro and in vivo for the purpose of silencing specific genes.The lab is also based on a team spirit that makes the environment stimulating and engaging while keeping it very friendly. We have lab parties and take an annual lab trip every summer to a destination chosen by the lab. Previous trips include "Mt St Helens climb" and "White water rafting on the deschutes".
- MSc, Univ. Paris XIII, Paris France 1988
- Ph.D., Colorado State University, Fort Collins Colorado 0 1999
Memberships and associations
- American InstituteOf Cancer Research American Association for Cancer Research
- "Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate : A Randomized Controlled Trial." Nutrition and Cancer In: , Vol. 68, No. 8, 16.11.2016, p. 1309-1319.
- "Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy." Cancer Prevention Research In: , Vol. 8, No. 12, 01.12.2015, p. 1184-1191.
- "Neurotransmitter CART as a new therapeutic candidate for Parkinson's disease." Pharmaceuticals In: , Vol. 6, No. 1, 18.01.2013, p. 108-123.
- "CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria." PLoS One In: , Vol. 7, No. 1, e29343, 03.01.2012.
- "Lysophosphatidic acid activates peroxisome proliferator activated receptor-γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1." PLoS One In: , Vol. 6, No. 4, e18932, 2011.
- "Monitoring human melanocytic cell responses to piperine using multispectral imaging." Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 7883 2011. 788309.
- "In vivo measurement of epidermal thickness changes associated with tumor promotion in murine models." Journal of Biomedical Optics In: , Vol. 15, No. 4, 041514, 07.2010.
- "In Utero Life and Epigenetic Predisposition for Disease." C ed. Unknown Publisher, 2010. 21 p. (Advances in Genetics; Vol. 71, No. C).
- "In vivo measurements of epidermal thickness by reflectance mode confocal microscopy to assess cellular proliferation induced by topical agents." Progress in Biomedical Optics and Imaging - Proceedings of SPIE. Vol. 7187 2009. 71870S.
- "Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans." Journal of Nutrition In: , Vol. 137, No. 5, 05.2007, p. 1188-1193.
- "Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer." Cancer Research In: , Vol. 66, No. 18, 15.09.2006, p. 9017-9025.
- "The effect of PPARγ ligands on UV- or chemically-induced carcinogenesis in mouse skin." Molecular Carcinogenesis In: , Vol. 43, No. 4, 08.2005, p. 198-206.
- "Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARγ in normal mouse skin keratinocytes." Journal of Investigative Dermatology In: , Vol. 123, No. 6, 12.2004, p. 1110-1119.
- "Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors." Biochemical Journal In: , Vol. 366, No. 3, 15.09.2002, p. 901-910.
- "The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death." Journal of NeuroVirology In: , Vol. 8, No. 4, 08.2002, p. 318-325.
- "Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886." Biochemical Journal In: , Vol. 356, No. 3, 15.06.2001, p. 899-906.
- "Activators of peroxisome proliferator-activated receptor-α partially inhibit mouse skin tumor promotion." Molecular Carcinogenesis In: , Vol. 29, No. 3, 2000, p. 134-142.
- "8s-Lipoxygenase products activate peroxisome proliferator-activated receptor α and induce differentiation in murine keratinocytes." Cell Growth and Differentiation In: , Vol. 11, No. 8, 2000, p. 447-454.
- "Peroxisome proliferator-activated receptors : A family of lipid-activated transcription factors." American Journal of Clinical Nutrition In: , Vol. 70, No. 4, 10.1999, p. 566-571.
- "A novel 3T3-L1 preadipocyte variant that expresses PPARγ2 and RXRα but does not undergo differentiation." Journal of Lipid Research In: , Vol. 39, No. 10, 10.1998, p. 2048-2053.
- "Cytosolic and nuclear distribution of PPAR-γ2 in differentiating 3T3- L1 preadipocytes." Journal of Lipid Research In: , Vol. 39, No. 12, 1998, p. 2329-2338.
- "Differential PPARγ2 and RxRα expression in the differentiating 3T3-L1 adipocyte." FASEB Journal In: , Vol. 11, No. 3, 1997.
- "MELAS syndrome with mitochondrial tRNA mutation : Correlation of clinical state, nerve conduction, and muscle P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin." Neurology In: , Vol. 42, No. 11, 1992, p. 2147-2152.
- "Deficiency of skeletal muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human muscle oxidative defect." Journal of Clinical Investigation In: , Vol. 88, No. 4, 1991, p. 1197-1206.